Clatacef Adverse Reactions

Cefotaxime is generally well tolerated. The most common adverse reactions have been local reactions following IM or IV injection. Other adverse reactions have been encountered infrequently.
Incidence greater than 1%: The most frequent adverse reactions include: GI: Occurrence, 1.4%: Colitis, diarrhea, nausea, and vomiting. Symptoms of pseudomembranous colitis can appear during or after antibiotic treatment. Nausea and vomiting have been reported rarely.
Hematologic: Occurrence, 2.4%: Eosinophilia.
Hypersensitivity: Occurrence, 2.4%: Fever, pruritus, rash, and, less frequently, anaphylaxis and urticaria.
Local: Occurrence, 4.3%: Injection site inflammation with IV administration. Pain, induration, and tenderness after IM injection.
Less frequent (incidence less than 1%) adverse reactions include: Cardiovascular: Potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration via central venous catheter have been observed.
CNS: Headache.
Dermatologic: As with other cephalosporins, isolated cases of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported.
GU: Moniliasis, vaginitis.
Hematologic: Agranulocytosis, eosinophilia, neutropenia, thrombocytopenia, and transient leukopenia have been reported. Some individuals have developed positive direct Coombs' tests during treatment with cefotaxime and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
Hepatic: Transient elevations in AST, ALT, serum lactate dehydrogenase, and serum alkaline phosphatase levels have been reported.
Renal: As with some other cephalosporins, interstitial nephritis and transient elevations of serum' urea nitrogen (BUN) and creatinine have been occasionally observed with cefotaxime.
Cephalosporin-class adverse reactions: In addition to the adverse reactions previously listed that have been observed in patients treated with cefotaxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: allergic reactions; aplastic anemia; false-positive test for urinary glucose; hepatic dysfunction, including cholestasis; and hemorrhage. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, discontinue the drug. Anticonvulsant therapy can be given if clinically indicated.